NOAC and VKA persistence were comparable before the end of the study in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) and Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation (ARISTOTLE) trials [6,7]. The gene discussed is F10; the disease is stroke disorder.